# Pizarra — PT-pseudo_d7d26761c714 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d7d26761c714
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 7.7 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.03 ng/mL/yr
  - Prior PSA: 4.6 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6079056 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7.7 ng/mL. PI-RADS 3. PSAD 0.11. Prostate volume 73 mL. csPCa 0.61.

Vitals: weight 86 kg, height 177 cm, BMI 27.5, BP 120/82 mmHg, HR 80 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to prior histological confirmation of malignancy and a recent PSA rise to 7.7 ng/mL.

History: At 64 years of age, this mechanical engineer entered surveillance protocols after a positive biopsy established ISUP Grade Group 1 carcinoma. Residing on an operational agricultural property alongside his spouse, his daily routine entails early hours and intermittent manual tasks, yet he characterizes his general mobility as largely sedentary with sporadic strolls. Lower urinary tract complaints are entirely absent, reflected by an IPSS score of 1. He explicitly denies haematuria, pelvic discomfort, or osseous pain. Cardiovascular parameters remain stable under valsartan and metoprolol therapy, a combination maintained for years. A minor knee arthroscopy performed in his late forties constitutes his sole surgical history, alongside a mild visual deficit necessitating large-print reading materials. Alcohol intake averages four units per week, and documented allergies remain absent. His long-standing companion acts as his designated next of kin. He abstains from tobacco entirely.

Physical examination: DRE — glandular assessment: symmetrically enlarged, uniformly smooth with firm consistency, devoid of discrete nodules or contour irregularities. General inspection: well-nourished adult, appearing comfortable without acute distress. Auscultation confirms clear pulmonary fields and a regular cardiac rhythm measuring 80 beats per minute. Vascular pressure registers 120/82 mmHg. Lower extremities show no pitting oedema, and lymphatic chains remain non-palpable.

Patient info: mechanical engineer; Married; Lives on a working farm with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 1/35 (mild LUTS).


Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.48 +/- 0.19   (95% CI 0.12-0.85)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=3.0, psa=7.7, age=64.0, psad=0.11, dre_ord=0.0, vol=73.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.03 ng/mL/yr) against the PI-RADS 3 score, which is a key factor in risk stratification. It also could not incorporate the prior positive biopsy status, which fundamentally changes the question from "does he have cancer" to "is the cancer progressing/recurrent/new," especially given the high csPCa probability (0.6079056). Finally, it missed the context provided by the retrieved documents, such as the full mpMRI report or the PSA history trend, which are crucial for interpreting the PI-RADS 3 in this context.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.48 +/- 0.19), placing it in the 'discuss' tier. This wide interval suggests the input data is highly ambiguous. A failure mode is the contradiction between the PI-RADS 3 score and the rising PSA (from 4.6 to 7.7 ng/mL), which might suggest progression despite the equivocal imaging. Another failure mode is ignoring the prior positive biopsy result; if the prior biopsy was for a low-grade cancer (ISUP Grade Group 1), the current high PSA and PI-RADS 3 might warrant re-evaluation, contradicting the prior's tendency to lean towards 'no'.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details suspicious features or extent, it would refine the PI-RADS 3 interpretation.
  <document> PSA history (trend) -> If the trend shows a rapid rise, it would increase the urgency for further investigation.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plans.
  <document> laboratory results (full panel) -> This could provide context on other markers that might influence the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d7d26761c714", "radiology_report": "Subject: Prostate Multiparametric MRI | Facility: Antoni van Leeuwenhoek Hospital | Date: 29 December 2024\nClinical Indication:\nFollow-up assessment for established malignancy. Current serum PSA measures 7.7 ng/mL. Previous histopathology confirmed ISUP Grade Group 1 disease.\nFINDINGS:\nThe gland exhibits a total volume of 73.0 mL, displaying symmetrical enlargement alongside uniform T2 weighting throughout the peripheral compartments. A discrete region of intermediate signal intensity occupies the left mid-gland peripheral zone, spanning roughly 12 x 10 mm. Diffusion-weighted imaging and ADC mapping reveal mild restriction within this focus, devoid of associated T2 signal loss. Dynamic contrast sequences demonstrate an absence of definitive early or sustained enhancement. Extracapsular dissemination and seminal vesicle infiltration remain unobserved. Pelvic lymph nodes appear normal, and skeletal structures show no metastatic foci.\nIMPRESSION:\nDiscrete abnormality localized to the left mid-gland peripheral compartment, assigned PI-RADS 3.\nCalculated PSA density: 0.11 ng/mL/mL.\nEstimated csPCa probability: 0.6079056"}

  **psa_trend**
  {"case_id": "PT-pseudo_d7d26761c714", "psa_trend": [{"date": "Dec 2022", "val": 5.3}, {"date": "Dec 2023", "val": 5.1}, {"date": "Jan 2025", "val": 7.7}]}

  **previous_notes**
  {"case_id": "PT-pseudo_d7d26761c714", "previous_notes": [{"date": "09 Jan 2024", "author": "Dr. F. de Boer (GP)", "text": "Initial consultation occurred after an elevated PSA reading of 6.0 ng/mL was recorded in late 2022. A repeat measurement in December 2023 indicated a decline to 4.6 ng/mL. Given the patient\u2019s age alongside the previously confirmed histological diagnosis, an mpMRI was scheduled and a referral to the urology outpatient department was submitted. Hypertension remains adequately managed with valsartan and metoprolol."}, {"date": "08 May 2024", "author": "Dr. F. de Boer (GP)", "text": "Subsequent visit addressed the urology referral pathway. The individual has completed imaging and pathological evaluation, with all documentation filed accordingly. Systemic health status remains stable, and the prescribed pharmacological regimen continues unchanged."}]}

  **lab_results**
  {"case_id": "PT-pseudo_d7d26761c714", "laboratory_results": [{"name": "PSA", "val": "7.7 ng/mL", "date": "07 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.93 ng/mL", "date": "07 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "07 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.2 g/dL", "date": "07 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.4 x10^9/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "236 x10^9/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "99 umol/L", "date": "07 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "07 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "10.4 nmol/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "89 U/L", "date": "07 Dec 2024", "flag": ""}, {"name": "LDH", "val": "193 U/L", "date": "07 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.5 %", "date": "07 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA: 7.7 ng/mL (Current value is elevated)
  - PSA velocity: 1.03 ng/mL/yr (Indicates a rising trend from 4.6 ng/mL)
  - csPCa predicted probability: 0.6079056 (High probability)
  - PI-RADS score: 3 (Equivocal, but warrants re-evaluation given clinical context)

  AGAINST sampling this patient now:
  - Prior biopsy: Positive (ISUP Grade Group 1 carcinoma)
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)

WHERE THIS LEANS
  The evidence suggests a need for re-evaluation due to the rising PSA and high predicted risk, despite the equivocal PI-RADS 3 score and the prior low-grade diagnosis. This leans against the statistical prior of 'NO BIOPSY' by highlighting clinical progression markers.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient has a prior positive biopsy for ISUP Grade Group 1 carcinoma, shifting the question to whether the cancer has progressed. This is supported by the rising PSA from 4.6 ng/mL to 7.7 ng/mL over 12 months and the PI-RADS 3 finding, which together indicate a need for re-evaluation despite the prior diagnosis.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
